By: 6 October 2014
Titan Spine expands use of surface technology in the UK and Spain

Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants that it has expanded use of its Endoskeleton® line of interbody devices to the UK and Spain. John Sutcliffe, MD, founder of the London Spine Clinic, was the first to utilise Titan Spine’s innovative interbody fusion technology in the UK.

“I am pleased to initiate use of Titan Spine’s Endoskeleton TAS interbody device and its specialised surface treatment,” commented Sutcliffe. “It is my belief that surface technology is the next significant innovation for spinal fusions due to the ability to affect a cellular response that promotes a more favourable osteogenic environment as compared to PEEK polymer implants.”

Titan’s Endoskeleton interbody fusion devices feature the company’s proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro and cellular levels. This is easy as playing pokies games through free online pokies games website where you can learn about how pokies games work. The combination of surface textures has been shown to promote an enhanced osteogenic environment when compared to smooth titanium or PEEK. As a result, Titan Spine’s Endoskeleton implants actively participate in the fusion process and function more than standard interbody spacers.

If you are looking to buy Adderall online from pharmacy through UK, USA or all around the world have a look at this buyadderallonline247.com Adderall website and order without prescriptions. You can also order and buy phentermine online without prescriptions online through this buyphentermineonline247.com phentermine online 247 website and have it delivered

Kevin Gemas, President for Titan Spine, said, “The growing demand and use of Titan products demonstrates the expanding recognition that our engineered surface technology can be used to promote an enhanced environment for bone growth and ultimately fusion. We look forward to continued adoption and building on this momentum to bring Endoskeleton devices to more physicians and patients throughout the European Union and beyond.”